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Commentaries

RANKing c-Jun in osteoclast development
Steven L. Teitelbaum
Department of Pathology, Washington University School of Medicine, St. Louis, Missouri, USA.

Pathological bone loss always reflects enhanced net osteoclastic activity. Recognition and binding of the receptor activator of NF-κB (RANK) by RANK
ligand (RANKL) is the key osteoclastogenic event, and the signaling cascades
induced by this reaction therefore contain potential anti-osteoporosis therapeutic targets. A study reported in this issue of the JCI documents that a pivotal component of RANKL/RANK-mediated osteoclast recruitment involves
sequential induction of the transcription factors c-Jun and nuclear factor of
activated T cells 2 (see the related article beginning on page 475).
What is an osteoclast?
Osteoporosis always represents an imbalance in favor of osteoclast-mediated bone
resorption relative to the bone-forming
capacity of osteoblasts. In some conditions
of accelerated skeletal loss, such as Paget
disease, osteoclasts are greatly enlarged,
which enhances the individual cell’s
resorptive activity. Most osteopenic disorders, however, develop as a consequence
of accelerated bone degradation due to
increased osteoclast number. Thus, inhibition of osteoclast formation by estrogen
supplementation, or osteoclast function by
bisphosphonate administration, has been
the most effective means of arresting pathological bone loss. However, both forms of
therapy are not without drawbacks, and new
anti-resorptive targets are rapidly emerging.
In this issue of the JCI, Ikeda et al. elegantly
show that the JNK-1–activated c-Jun signaling pathway is key to osteoclastic bone
resorption (1). The authors find that mice
bearing a dominant-negative osteoclast-specific c-Jun transgene have impaired osteoclastogenesis and, because of failed bone
resorption, develop increased bone mass in
the form of osteopetrosis. Importantly, the
failure of dominant-negative c-Jun transgenic mice to generate osteoclasts is due to
arrested activation and expression of members of the nuclear factor of activated T cells
(NFAT) family of transcription factors in
osteoclast precursors.
Nonstandard abbreviations used: activator protein1 (AP-1); MAPK kinase 7 (MKK7); nuclear factor of
activated T cells (NFAT); receptor activator of NF-κB
(RANK); RANK ligand (RANKL); TNF receptor–associated factor 6 (TRAF6).
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The osteoclast is a huge cell whose phenotype is characterized by its capacity to
attach to bone and polarize its resorptive
machinery toward the cell’s interface with
mineralized matrix (2). It is a terminally
differentiated polykaryon whose multinucleation is a manifestation of fusion rather
than endomitosis, and it is the unique
resorbing cell of the skeleton.

particularly TNF-α, may be profoundly
synergistic, only activated RANKL/RANK
signaling suffices and is essential for
osteoclast differentiation (8, 9).
The discovery of the osteoclastogenic
capacity of RANKL enables generation of
large numbers of essentially pure populations of bona fide osteoclasts in vitro,
which in turn permits meaningful biochemical and molecular definition of
this cell. We now know that RANKL is a
homotrimer (7), which not only promotes
differentiation of osteoclast precursors but
also activates the mature bone-degrading
polykaryon (10). Thus, RANKL and RANK,
as well as their intracellular signaling pathway, are presently the most promising antiresorptive therapeutic targets.

RANK ligand is key
Donald Walker, in the 1970s, performed
the first meaningful experiments with
osteopetrotic mice, which have, from
that time forward, served as the essential resource for understanding how
osteoclasts are born, resorb bone, and
die. Using cross-circulation and marrow cell transplantation, Walker established that the enigmatic polykaryon is
of hematopoietic origin (3). A decade
later, Suda’s group documented that the
osteoclast can be generated, in vitro, from
mononuclear members of the monocyte/
macrophage family, thus establishing their
identity as osteoclast precursors (4). Curiously, however, Suda was unable to generate osteoclasts unless their mononuclear
progenitors were in physical contact with
marrow-derived mesenchymal stromal
cells, including osteoblasts. Discovery of
the molecule expressed on the surface of
stromal cells that mediates commitment
of macrophages to the bone resorptive
phenotype remained the principal enigma
of osteoclast biology until 1998, when this
key osteoclastogenic moiety was identified
as receptor activator of NF-κB (RANK)
ligand (RANKL) (5, 6). RANKL is a member of the TNF superfamily whose crystal
structure reveals unique components that
enable it to activate its osteoclastogenic
receptor, RANK, on osteoclast precursors (7) (Figure 1). While other cytokines,

The osteoclast needs
TRAF6, Fos, and Jun
The importance of activator protein-1
(AP-1) transcription factors, specifically
dimers of the Fos and Jun families of
proteins, in the osteoclastogenic process
was first documented in the laboratory
of Erwin Wagner, wherein c-Fos knockout
mice were shown to be osteopetrotic due
to a complete absence of osteoclasts (11).
Consequently, the discovery of RANKL
as the key osteoclastogenic cytokine
prompted interest in the mechanisms by
which RANK activation regulates AP-1
transcription factors.
Just why RANKL is unique among TNF
superfamily members in its capacity to
induce osteoclast differentiation is still
unresolved but probably involves its interaction with TNF receptor–associated factor 6
(TRAF6) (12, 13). Other RANKL-stimulated
intracellular signaling molecules essential to
the osteoclast phenotype include the p50/
p52 NF-κB subunits and the PI3K/AKT axis.
Similarly, the MAPKs extracellular regulated
kinases 1 and 2 and p38 are required for
osteoclast differentiation or function.
Association of RANKL and TRAF6 activates all key events involving AP-1–mediated transcription of osteoclast specific
genes. Expression of the c-Fos gene in 393T
cells requires TRAF 6, but whether the same
holds true in osteoclasts is unresolved. On
the other hand, c-Jun is clearly RANKL
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Figure 1
The AP-1/NFAT transcription complex mediates osteoclast precursor differentiation. Osteoclastogenesis is initiated by RANKL occupying RANK on the surface of osteoclast precursors.
Subsequent recruitment of TRAF6 initiates the 3 depicted signaling cascades, in addition to
other pathways not shown here. Phosphorylation (P) activates c-Jun in an MKK7/JNK-1–dependent manner, and NFAT1 is activated by dephosphorylation via calcium-mediated induction
of calcineurin. RANKL/RANK also induces c-Fos expression by an incompletely understood
mechanism. NFAT1 partners with the AP-1 proteins of the Fos/Jun families to transactivate the
NFAT2 gene, the product of which forms a similar ternary transcription complex on osteoclastic
genes eventuating in appearance of the mature osteoclast phenotype.

activated via TRAF6 by a process involving JNK1 but not JNK2 (14). c-Jun is not
the only member of its family to regulate
osteoclastogenesis, as Jun-B–deficient mice
also have arrested bone resorption (15).
When transcriptionally active, c-Jun associates with members of the Fos family of
transcription factors, a number of which
— such as Fra-1, itself a c-Fos target — may
substitute for c-Fos in the osteoclastogenic
process (16). Although c-Jun also homodi464

merizes, the fact that c-Jun overexpression
does not rescue the c-Fos–/– osteopetrotic
phenotype indicates that c-Jun is necessary, but not sufficient, to transactivate
osteoclast specific genes.
NFAT and AP-1
In 2002 Takayanagi et al. identified NFAT2
by genome-wide screening as the predominant gene activated in osteoclast precursors
under the influence of RANKL and docu-
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mented the transcription factor’s essential role in osteoclastogenesis (17). RANK
occupancy mobilizes intracellular calcium,
a requisite for calcineurin-mediated NFAT
activation (Figure 1). Moreover, RANKL
not only induces the transcription factor’s
expression but facilitates its nuclear translocation, where NFAT binds to its DNA
response element via a ternary complex
with AP-1 proteins, including Fos/Jun, to
transactivate target genes (18). Thus, it is
not surprising, in retrospect, that RANKLinduced osteoclastogenesis involves partnering of Fos/Jun with NFAT2. The fact
that Ikeda et al. (1) found that expression of
NFAT2 itself is NFAT1/Fos/Jun–dependent
is in keeping with the presence of NFAT and
AP-1 response elements in the NFAT2 promoter (19). Reflecting its role as an essential RANKL-activated signaling molecule,
NFAT2, when overexpressed in wild-type
macrophages, prompts osteoclast differentiation in the absence of the osteoclastogenic cytokine (17). RANKL-stimulated
gene transcription is, therefore, a reflection
of NFAT partnering with Fos/Jun.
Thus, Ikeda et al. (1) provide evidence of
important components of RANK-mediated
osteoclastogenesis specifically as it pertains
to the AP-1 transcription complex. Clearly,
TRAF6 is an essential player in RANKLmediated c-Jun and NFAT activation and,
perhaps, c-Fos expression. NFAT/Fos/Jun
is a critical osteoclastogenic complex,
and deletion of any of the three arrests
osteoclast formation. The pivotal role that
Ikeda et al. document for c-Jun in osteoclast
formation is in keeping with the fact that
the anti–bone resorptive effects of estrogen
are substantially mediated by c-Jun repression (20). Given that RANKL expression is
also enhanced in estrogen-deficient women
(21), RANKL → TRAF6 → MAPK kinase 7
(MKK7) → JNK1 → Jun → NFAT signaling
is likely pivotal to the pathogenesis of postmenopausal osteoporosis, and inhibition
of any of the components will theoretically
arrest accelerated bone resorption (Figure
1). The therapeutic challenge is how to specifically target these intracellular signaling
molecules in osteoclasts.
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AMP-activated protein kinase:
the guardian of cardiac energy status
D. Grahame Hardie
Division of Molecular Physiology, Faculty of Life Sciences, Wellcome Trust Biocentre, University of Dundee, Dundee, United Kingdom.

Several years ago it was proposed that the AMP-activated protein kinase
cascade might protect cells against stresses that deplete cellular ATP.
Young et al. have now directly tested this by studying the effects of ischemia and reperfusion in perfused hearts from mice expressing a dominant-negative mutant that suppresses the kinase activity in cardiac muscle
(see the related article beginning on page 495). Compared with control
hearts, the mutant hearts showed clear evidence for increased necrotic
damage and increased apoptosis. These findings may have implications
for the treatment of ischemic heart disease.
AMP-activated protein kinase (AMPK) is
the downstream component of a protein
kinase cascade that is highly conserved
in all eukaryotic cells (1). AMPK is activated by the rising cellular AMP that (due
to the action of adenylate kinase) always
accompanies a fall in the cellular ATP/
ADP ratio, and this activation is antagonized by high concentrations of ATP
(Figure 1). Downstream targets and processes regulated by the kinase are being
identified on a regular basis (Figure 2).
Nonstandard abbreviations used: 5-aminoimidazole4-carboxamide riboside monophosphate (ZMP); AMPactivated protein kinase (AMPK).
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In general, AMPK switches off ATP-consuming processes such as biosynthetic
pathways, while switching on catabolic

processes that generate ATP, including
cellular uptake of glucose (2) and fatty
acids (3) and increased fatty acid oxidation (4) in the heart.
The first evidence that AMPK was activated by metabolic stresses appeared 13
years ago, when my group found that
AMPK was activated by ATP depletion
caused by incubation of isolated rat
hepatocytes with high fructose (5), while
Witters et al. (6) reported that it was activated by various metabolic poisons in
hepatoma cells. We proposed at the time

Figure 1
Role of AMPK in regulating energy balance at the single-cell level. The way in which the AMPK
system controls the balance between ATP consumption (e.g., by biosynthesis, cell growth, or
muscle contraction) and ATP production via catabolism is illustrated. If the rate of ATP consumption exceeds its rate of production, ADP will tend to rise and be converted to AMP by the
enzyme adenylate kinase. The rise in level of the activating ligand AMP, coupled with the fall in
level of the inhibitory nucleotide ATP, activates AMPK, which then switches off ATP-consuming
processes and switches on catabolism in an attempt to redress the balance.
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